Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.
23andMe completes $150mm Series E financing
23andMe Inc., which sells DNA testing kits directly to consumers who contribute their data to large-scale genetic research, raised...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.
